Abstract. A recombinant protein containing part of the dengue (DEN) 2 envelope protein was evaluated as a subunit immunogen for vaccination against DEN virus infection. A gene fragment encoding amino acids 298-400 (B domain) of the DEN-2 virus envelope was expressed as a fusion protein with the maltose binding protein (MBP) of Escherichia coli. This recombinant, DEN-2(B)/MBP, was purified and analyzed for its antigenicity, immunogenicity, and ability to protect mice against lethal challenge. The recombinant antigen reacted with a DEN-2 type-specific neutralizing monoclonal antibody (3H5), DEN-2 hyperimmune mouse ascitic fluid, and DEN-2 immune human sera. When administered to mice, DEN-2(B)/MBP elicited a DEN-2 virus neutralizing antibody response that conferred partial protection against challenge infection with a lethal dose of DEN-2 virus administered by intracranial inoculation. In addition, no replication of DEN-2 virus was detectable in the brains of the immunized mice as compared with control mice that were killed six days after challenge. Sera from immunized mice revealed no cross-neutralizing antibody to any of the other DEN serotypes in the plaque-reduction neutralization test. These findings warrant further studies with the DEN-2(B)/MBP antigen as a potential human vaccine candidate. An effective vaccine could prevent thousands of cases of illness and many deaths each year resulting from DEN virus infections.
Dengue (DEN) virus infections are a major public health problem throughout the tropical and subtropical areas of the world. Four serotypes of DEN virus have been identified (DEN-1, 2, 3, and 4), and each of these serotypes can infect humans and cause disease. Disease manifestations range from mild undifferentiated acute fever to severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). 1, 2 The occurrence of DHF/DSS has been strongly associated with sequential infections of the same individual with two different serotypes of DEN virus. A primary infection with any serotype of DEN virus appears to confer immunity against reinfection with the same serotype, but only short-term immunity is induced against heterologous DEN virus serotypes. [3] [4] [5] [6] [7] Serotype-specific and cross-reactive neutralizing antibodies are thought to be an important component of protective immunity following primary DEN infection. Presumably, after the cross-reactive levels of neutralizing antibodies decrease below the protective level, an individual can become infected with a different DEN virus serotype. During this secondary DEN infection, individuals are at higher risk for developing DHF/DSS. Antibody-dependent infection enhancement has been proposed as the mechanism responsible for inducing severe disease associated with secondary DEN infections. Apparently, infection with the second DEN serotype can be enhanced by the presence of non-neutralizing cross-reactive antibody acquired during the previous infection with a different serotype. 1, 8 These heterologous antibodies are thought to form immune complexes with the serotype of DEN virus responsible for the second infection and enhance the uptake of virus by the main cellular target, mononuclear phagocytic cells, via Fc receptors. Because of the possibility of immune enhancement associated with secondary and possibly tertiary DEN infections, 9 an effective vaccine should ideally induce sustained high titers of serotype specific neutralizing antibody against all four serotypes of DEN virus to insure that it does not enhance subsequent infections from natural exposure to dengue viruses.
Since natural DEN virus infections induce solid serotype specific immunity, live-attenuated virus strains are theoretically the most promising approach to developing an effective DEN vaccine. However, in spite of ongoing research efforts over the past 50 years, no live-attenuated dengue vaccine is currently approved for human use. In recent years, considerable research effort has also been directed towards the development of subunit DEN vaccines. Numerous reports are available describing the production of recombinant proteins in expression vectors including baculovirus, vaccinia virus, and Escherichia coli, and several promising candidates have protected mice from homologous DEN challenge. [10] [11] [12] [13] [14] [15] [16] [17] [18] It remains unknown, however, whether or not immunity induced by a subunit vaccine would induce long-term protection against reinfection. A theoretical safety concern is the possibility that over time homologous neutralizing antibody levels induced by the subunit vaccine would decrease below protective levels while heterologous enhancing antibody levels still persisted. One approach that has been suggested to minimize the possibility of antibody-dependent infection enhancement occurring after vaccination is to design a tetravalent subunit DEN vaccine that contains epitopes that induce high levels of specific neutralizing antibody to all four serotypes, but contains a minimum of DEN complex crossreactive epitopes that presumably are responsible for the induction of enhancing antibody. 19, 20 Fonseca and others 21 showed that the B domain of the DEN envelope protein expressed as a recombinant fusion protein with the trpE protein of E. coli was antigenic. These trpE-DEN proteins for each of the four serotypes of DEN virus reacted strongly with hyperimmune mouse ascitic fluid (HMAF) against the homologous serotype of DEN virus, but showed little or no cross-reactivity with heterologous DEN serotype antibody. However, the trpE-DEN recombinant proteins were not immunogenic when tested in mice. In the current study, we have subcloned the B domain of the DEN-2 envelope as a fusion protein with the maltose binding protein (MBP) of E. coli and have shown it to be highly immunogenic and protective in the mouse model. 
MATERIALS AND METHODS
Viruses and antisera. Cell culture supernatant harvested from Vero cells infected with DEN-I (West Pac), DEN-2 (New Guinea C), DEN-3 (CH53489), DEN-4 (341750), and yellow fever virus (YF vaccine strain 17D) strains were used as virus stocks. The nine mouse monoclonal antibody ascitic fluids used in this study (Table 1 ) have previously been described. [22] [23] [24] [25] [26] [27] Polyclonal HMAF against each of the four DEN virus serotypes were obtained from the American Type Culture Collection (Rockville, MD).
Plaque-reduction neutralization assay. Plaque-reduction neutralization tests (PRNTs) and plaque assays were performed as previously described. 28, 29 For neutralization assays, monkey kidney (LLC-MK2) cell monolayers were seeded in six-well plates (Falcon; Becton Dickinson, Lincoln Park, NJ). Plates were incubated at 37ЊC in a CO 2 incubator. Sera from immunized mice were tested using two-fold dilutions starting at 1:10. Plaques were visualized on day 7 by staining with 0.02% neutral red in Hanks' balanced salt solution. Each mouse serum was tested in duplicate and the number of plaques reported was the average of the two determinations. The percent reduction of plaques was calculated by comparison of the results obtained with sera from unimmunized mice.
Recombinant DNA technology and construction of an expression plasmid. Extraction, purification, and transformation of DNA were as described by Sambrook and others. 30 The pATH plasmid containing DEN-2 cDNA (pATH-2) has been described and was kindly provided by Dr. P.W. Mason (Yale University, New Haven, CT). 21 Synthetic oligo sense and antisense primers containing suitable restriction sites (Xmn I and Hind III) were used for the amplification of the region encoding the B domain, amino acids 298-400, of the DEN-2 envelope protein. Polymerase chain reaction amplification was done using the pATH-2 plasmid DNA as a template and the oligo primers for 35 cycles at 94ЊC for 1 min, 56ЊC for 1 min, and 72ЊC for 2 min. The amplified fragment was cut with Xmn I and Hind III, and ligated to Xmn I/Hind III cut pMAL-c2 expression vector (New England Biolabs, Beverly, MA). This vector contains the mal E gene of E. coli, which encodes MBP upstream from the insertion site for the DEN-2 B domain gene resulting in the expression of the cloned gene as an MBP fusion protein (DEN-2(B)/MBP). The recombinant plasmids were used to transform E. coli TB1. Several positive (white color) bacterial colonies were chosen and analyzed for the presence of the DEN-2 B domain gene segment by restriction enzyme analysis. Expression of the DEN-2(B)/MBP fusion protein was determined by the induction of positive bacterial cultures with isopropyl-␤-D-thiogalactopyranoside (IPTG), and immunoblot analysis using DEN-2 HMAF confirmed its specificity. The nucleotide sequence at the junction region between inserted cDNA and the MBP gene of the recombinant plasmid was examined for its reading frame by the dideoxynucleotide chaintermination method using a Genesis 2000 DNA Analysis System (DuPont, Wilmington, DE). 30, 31 Preparation and purification of the fusion protein. A 10-ml overnight bacterial culture containing the fusion plasmid was inoculated into one liter of LB broth containing 0.2% glucose and ampicillin (100 g/ml). The culture was grown in a shaker at 37ЊC to an A 600 of approximately 0.6. After induction with 0.5 mM IPTG for 3 hr, bacteria were harvested by centrifugation at 9,000 rpm for 15 min at 4ЊC, resuspended in 50 ml of column buffer (10 mM Tris-HCI, pH 7.4, 200 mM NaCl, 1 mM EDTA), and frozen at Ϫ20ЊC overnight. The bacterial suspension was thawed on ice and sonicated for 2 min with 20-sec pulses. The supernatant obtained after centrifugation of the sonicated cells at 9,000 rpm for 15 min at 4ЊC was loaded onto a amylose resin column. The column was washed with eight volumes of column buffer and the fusion protein was eluted with column buffer containing 10 mM maltose (Sigma, St. Louis, MO). The appropriate fraction was collected and concentrated using a Centricon concentrator (Amicon, Beverly, MA). Further purification was achieved by fractionation on a 10% preparative sodium dodecyl sulfate (SDS) polyacrylamide gel using nonreducing sample buffer. 32 Part of the gel was stained with Coomassie brilliant blue and the fusion protein band was excised and eluted from the gel using a Centrilutor (Amicon). Electroelution was done in 0.5ϫ electrophoresis buffer at room temperature for 3 hr at 20 mA. 32 The eluted fusion protein was dialyzed for 24 hr against several changes of phosphate-buffered saline (PBS) and concentrated with a Centriprep 30 (Amicon), aliquoted and frozen at Ϫ20ЊC. Protein concentration was determined using the bicinchoninic acid protein assay (Pierce, Rockford, IL).
Cleavage with factor Xa. The pMal-c2 expression vector contains the sequence coding for the recognition site of the protease factor Xa, located between the malE gene and the polylinker insertion sites. This allows cleavage of the MBP carrier and the protein of interest. The DEN-2 envelope B domain fragment was cleaved from the MBP protein by adding (1% w/w) Xa protease in 500 l of buffer containing 20 mM Tris-HCI, pH 7.4, 200 mM NaCl, 1 mM EDTA, 2 mM CaCl 2 , pH 8.0, and incubated for 24 hr at room temperature on a shaker. The cleavage mixture was applied to a 16% preparative SDS-polyacrylamide gel, 32 electrophoresed, and the appropriate band purified as described.
Gel electrophoresis and Western blot. Proteins were re-solved on 4-20% SDS-polyacrylamide gels (Novex, San Diego, CA) and either stained with Coomassie blue or transferred to polyvinylidene membranes as previously described. 32, 33 For the immunoblot, membranes were blocked with 5% nonfat dry milk in PBS/0.01% Tween 20 for 1 hr at room temperature and incubated at 4ЊC overnight with primary anti-DEN mouse antibody at a 1:100 dilution. To visualize antigenically reactive bands, the membranes were incubated with peroxidase-labeled goat anti-mouse IgG (Boehringer Mannheim, Indianapolis, IN) for 1 hr at room temperature and developed with 3,3',5,5'-tetramethylbenzedene (TMB; Kirkegaard & Perry, Gaithersburg, MD) substrate. Enzyme-linked immunosorbent assay. The analysis of sera from immunized mice for DEN-2 antibodies was carried out by ELISA as previously described. 34 Briefly, microtiter plate wells were coated with DEN-2 infected or uninfected Vero cell lysates diluted in PBS at 4ЊC overnight. Remaining sites were blocked with 5% nonfat dry milk in PBS/0.01% Tween 20 for 1 hr at 37ЊC. Plates were then incubated with the test sera in blocking buffer for 1 hr at 37ЊC at a 1:100 dilution. The secondary antibody was peroxidase-conjugated goat anti-mouse IgG (Boehringer Mannheim) diluted in blocking solution and incubated for 1 hr at 37ЊC. The 2.2'-azino-di(3-ethyl-benzthiazoline sulfonate(6) (ABTS) peroxidase substrate system (Kirkegaard & Perry) was used to visualize DEN-2-specific antibody. The net optical density (OD) values were determined by subtracting the absorbance of test serum with negative control antigen from the absorbance of test serum with the dengue antigen. The cut-off value for seropositivity was set at Ն 0.10 since the mean adjusted OD ϩ 3 standard deviations for the negative control sera and ascitic fluids was consistently below this value. The same procedure was used to characterize the reactivity patterns of the recombinant antigens in the ELISA with polyclonal and monoclonal mouse ascitic fluid and human immune sera. In these experiments, the microtiter plate wells were coated with DEN-2(B)/MBP, cleaved DEN-2 B domain fragment, or MBP alone.
Mouse immunizations. The protein preparations were emulsified in Titermax adjuvant (Cytrex Corporation, Norcross, GA) and groups of six-week-old, female, BALB/c mice (Jackson Laboratory, Bar Harbor, ME) were inoculated on days 0, 15, and 29 subcutaneously (footpad) with 50 g of 1) DEN-2(B)/MBP fusion protein (n ϭ 10), 2) cleaved DEN-2 B domain fragment (n ϭ 10), and 3) MBP (n ϭ 9). Another group of mice was inoculated intramuscularly with 50 g of DEN2(B)/MBP fusion protein (n ϭ 6) adsorbed on 0.1% aluminum hydroxide. Blood was withdrawn from the retro-orbital sinus on days 0, 14, 28, 43, 50, 57, and 64. Sera were assayed for DEN-2 antibodies by ELISA and PRNT.
The mouse protection assay was done using three-weekold, female, BALB/c mice. Groups of nine mice each were immunized subcutaneously with 50 g of DEN-2(B)/MBP or MBP emulsified in Titermax as described previously. Immunizations were performed on days 0, 7, and 14. Mice were bled on day 21 and challenged by intracranial inoculation using 30 l of a 1:100 dilution of a 20% suspension of DEN-2 (New Guinea C) virus-infected suckling mouse brain. The challenge preparation contained 100 mouse 50% lethal doses (LD 50 ) of DEN-2. Four mice in each group were killed on day 6 after challenge, and a 1:10 dilution of brain tissue was analyzed for the presence of virus by direct plaquing in LLC-MK 2 cell cultures. 29 The remaining mice were observed daily for 20 days and the dates of death were recorded.
The research protocol using animals in this study has been reviewed and approved by the Naval Medical Research Institute's Committee according to the principles set forth in the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animals, NIH Publication no. 92-3415. Figure 1B and 1C, respectively) . When used as an antigen in the ELISA, the DEN-2/MBP was strongly reactive with DEN-2 HMAF, the 3H5 and 6B6 DEN-2 serotype-specific monoclonal antibodies, and the human sera pool (Table 1) . This fusion protein also showed weak reactivity with the DEN-1 HMAF, but did not react with the DEN-3 and DEN-4 HMAF or any of the flavivirus group/subgroup reactive monoclonal antibodies. The cleaved DEN-2 fragment tested with the DEN-2 HMAF, monoclonal antibody 3H5, and the positive human pool, was unreactive with the mouse antibody preparations and showed reduced reactivity with the human sera pool.
RESULTS

Characterization
Serum antibody responses. Mice inoculated subcutaneously in the footpad with the DEN-2(B)/MBP fusion protein as well as the cleaved DEN-2 B domain fragment in Titermax showed an IgG antibody response against DEN-2 in the ELISA using an infected Vero cell lysate antigen (Figure 2 ). Antibody levels measured by ELISA were minimal after the first dose and peaked at 2-3 weeks after the third dose (days 43-50). Both groups immunized with DEN-2(B)/MBP fusion protein showed a lower level of reactivity than the group immunized with the DEN-2 B domain fragment. The group of mice immunized intramuscularly with DEN-2(B)/ MBP on alum maintained their peak titer through day 64, while the other groups showed a decrease in antibody response. Serum from individual mice collected on day 50 postimmunization with DEN2(B)/MBP in Titermax were tested in the ELISA against all four serotypes of DEN to detect the presence of cross-reactive antibody (Figure 3 ). Two mice each had detectable antibody against DEN-1 and DEN-4 viruses.
High neutralizing antibody titers were detected on days 57 and 64 after the first inoculation in all mice immunized with the DEN-2(B)/MBP protein in Titermax (Table 2 ). In contrast, only five of 10 mice immunized with the DEN-2 B domain fragment developed neutralizing antibody, and the titers were substantially lower than seen with the DEN-2(B)/ MBP fusion protein. No cross-neutralizing antibody was detected in mice inoculated with the DEN-2(B)/MBP fusion protein in Titermax when tested in the PRNT against DEN 1, 3, and 4 viruses and yellow fever viruses using the day 57 sera pooled from all 10 mice. For the six mice immunized intramuscularly with DEN-2(B)/MBP on alum, five had neutralizing antibody titers (log 10 ) against DEN-2 Ͼ 3.11 and one had a titer of 2.62 when tested three weeks after the last inoculation.
Mouse protection experiment. The mouse DEN-2 encephalitis model was used to study the protective immunity of the recombinant DEN-2(B)/MBP fusion protein expressed in E. coli (Figure 4) . In this experiment, four (80%) of five mice immunized with recombinant DEN-2(B)/MBP fusion protein were protected against lethal challenge with virulent DEN-2 virus. All five (100%) mice immunized with the MBP control were dead by day 9 postchallenge. The plaque assays of brain tissue from mice killed six days after challenge revealed no detectable virus in mice immunized with DEN-2(B)/MBP at a 1:10 dilution. In the MBP control group, however, DEN-2 virus was detected in all four mice (Table 3) . DISCUSSION These results show that the B domain of the DEN-2 envelope expressed as a fusion protein with MBP from E. coli can induce high titers of neutralizing antibody and protective immunity in mice against DEN-2 virus. Cleavage of MBP reduced the immunogenicity of the DEN-2 B domain fragment for the induction of neutralizing antibody against DEN-2 virus, but did not reduce its ability to induce antibody reactive in the ELISA with DEN-2 virus-infected cell lysate antigen. In fact, sera from mice immunized with the DEN- Sequence data from the N terminal of the DEN-2 fragment were compatible with the presence of the first 18 amino acids including the cysteine residue at position 302 (Ching WM, unpublished data). We did not sequence the C terminal; however, the reactivity of this fragment with monoclonal antibody 3H5 in the Western blot assay indicates that most of this end is intact since at least part of the epitope recognized by 3H5 has been mapped to the amino acids sequence 386-397 of the envelope protein. 35 These results indicate that the failure of this sequence to be recognized on the DEN-2 fragment by 3H5 in the ELISA is because it is not being presented correctly to allow binding by the monoclonal antibody, and that the presence of the MBP moiety allows the DEN-2 fragment to assume a more native-like conformation.
Clearly, DEN-2-specific neutralizing epitopes are present and being recognized on the DEN2(B)/MBP fusion protein, as shown by the induction of high-titered DEN-2-specific neutralizing antibody in immunized mice and the reactivity of this antigen in the ELISA with the DEN-2 type-specific neutralizing monoclonal antibodies 3H5 and 6B6. Several other DEN-2-specific neutralizing monoclonal antibodies also have been mapped to the B domain of the DEN-2 virus envelope protein. 26 Although DEN virus cross-neutralizing antibody was not detected, DEN-1 or DEN-4 cross-reactivity was observed in the ELISA with some of the mice immunized with the DEN2(B)/MBP fusion protein. This protein also showed a low level of reactivity with DEN-1 HMAF in the ELISA, supporting the presence of some DEN virus subcomplex epitopes. The DEN-2(B)/MBP recombinant antigen did not react in the ELISA with several flavivirus group or subgroup specific monoclonal antibodies. In contrast to our results, a study on the immunoreactivity of a trpE fusion protein containing amino acids 298-397 of the DEN-2 viral envelope protein reported that a number of flavivirus group/ subgroup monoclonal antibodies, including 4G2, reacted with the fusion protein in an immunoblot assay. 26 Whether or not these results reflect differences in serologic assays (ELISA versus immunoblot), differences in the carrier protein fused to the DEN-2 sequences, MBP versus trpE, or differences in the length of the DEN-2 fragments themselves (amino acids 298-400 versus 298-397), remains to be determined. Unlike the DEN-2(B)/MBP fusion protein, DEN envelope sequences, including DEN-2 amino acids 298-400, fused to the trpE protein of E. coli have not been shown to be immunogenic in animals. 21, 26 The high type-specific neutralizing antibody titers observed in mice immunized with the DEN2(B)/MBP fusion protein and its low potential for inducing cross-reactive antibodies against the heterologous DEN virus serotypes indicate that the DEN-2(B)/MBP recombinant protein deserves further study as a potential subunit DEN vaccine candidate. Studies on immunogenicity and protective efficacy in subhuman primates will be conducted with the DEN-2(B)/MBP recombinant protein to determine if long-term type specific neutralizing antibody memory is established and if any cross-reacting antibodies induced following immunization are enhancing for heterologous DEN serotypes. Recombinant proteins containing the B domains of DEN-1, DEN-3, or DEN-4 fused to MBP also are being constructed and will be tested for immunogenicity and protective efficacy in mice with the ultimate goal of combining all four serotypes for a tetravalent vaccine against DEN.
